Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
11 déc. 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
09 nov. 2017 08h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are...
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
24 oct. 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis-- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) --...
Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
07 sept. 2017 08h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are...
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
01 août 2017 16h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of...
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
26 juil. 2017 19h30 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of...
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
14 juin 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in...